Drugs affected by Wegovy sales, may take court action

Copenhagen, Denmark – Obese Drugs Novo nordisk On Thursday, the rampant growth of complex drug addiction was harmed by the sale of Wegovy, and warned that he was considering legal action against companies that are believed to violate their intellectual property.

US pharmacies in the United States have made it possible to produce legal copies of Vega and Diabetes Novo drugs, which are chemically known as semaglutide, with a deficiency of drugs supplying food and medicines.

Last month, the FDA announced a deficit, however, giving complex pharmacies until May 22 to stop the sale of drug copies. Steming the lifting A similar label deficit on the competitor Eli Lily Zepbound in December.

Director -General Lars Frugard Jorgensen said that efforts to strengthen the supply of wildly popular drug drugs led to the removal of drugs from the drug deficiency list.

“Given the significant increase in the composition in the US, it seems to affect the vega recipe in 2025,” said Frugard Jorgensen at the firm’s annual meetings in Copenhagen, Denmark.

“We also take legal actions against these compounds because we believe that they violate our Islands (intellectual property) and, as such, harm our businesses,” he added.

The discussion provoked a legal battle between the two pharmaceutical giants and the narcotic units of the outsourcing association (ofa), which seeks to maintain the rights to receive profitable drugs.

Apho christened The decision of the FDA announce the end of the deficit “ill -advised and arbitrary”, adding that “deprive patients of vital treatment of type 2 diabetes, obesity, cardiovascular disease and other serious medical conditions.”

Demand for obesity drugs, including HIMS & Hers television firm, has false balls against high costs and short -term branded procedures. Such products are there not FDA approvedHowever, that is, the agency does not consider them for safety, efficiency and quality before they are sold.

Fruergaard Jørgensen said on Thursday that Novo Nordisk analysis revealed “impurities and even prohibited products” in some complex products without naming any specific manufacturers.

“It’s not Semaglutide,” he said, citing complex alternatives. “There are only one semaglutide, and patients should really check the products before they introduce them.”

Follows from the FBI prevention In February, the fake complex weight loss drugs claiming that they contain semaglutide, which include “complex mixtures of unknown drugs that do not contain semaglutide, high impurities, as well as dangerous or unauthorized drugs.”

Fruergaard Jørgensen said he was optimistic that patients would return to branded vegov and azempsic procedures as deliveries are becoming more affordable. Earlier this month, the Danish pharmaceutical firm launched a new Internet Optional Consumer Offering Wegovy for less than half the cost, trying to attract users from cheaper sophisticated copies.

“We scale the supply, so we are now not inferior to the FDA shortage.

Novo Nordisk seeks to reassure investors in their permanent market leader against the background of increasing competition and a number of disappointing tests for obesity, which once shot down the high price of the company.

Last month company report Better than expected, the fourth quarter income against the backdrop of high demand for its Wegovy obesity medicines, but predicts a slight slowdown in 2025.

Novo Nordisk shares closed 3.8% on Thursday after AGM.